Terms: = Ovarian cancer AND POLE, POLE1, 5426, FLJ21434, DKFZp434F222, ENSG00000177084 AND Treatment
57 results:
1. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Giudice E; Huang TT; Nair JR; Zurcher G; McCoy A; Nousome D; Radke MR; Swisher EM; Lipkowitz S; Ibanez K; Donohue D; Malys T; Lee MJ; Redd B; Levy E; Rastogi S; Sato N; Trepel JB; Lee JM
Nat Commun; 2024 Mar; 15(1):2805. PubMed ID: 38555285
[TBL] [Abstract] [Full Text] [Related]
2. Integration of the Molecular Classification of Endometrial Carcinoma to Select Patients for Fertility Sparing Strategies.
Bani MA; Maulard A; Morice P; Chargari C; Genestie C
Anticancer Res; 2024 Feb; 44(2):445-452. PubMed ID: 38307584
[TBL] [Abstract] [Full Text] [Related]
3. Exploring Co-occurring pole Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
Shah SM; Demidova EV; Ringenbach S; Faezov B; Andrake M; Gandhi A; Mur P; Viana-Errasti J; Xiu J; Swensen J; Valle L; Dunbrack RL; Hall MJ; Arora S
Cancer Res Commun; 2024 Jan; 4(1):213-225. PubMed ID: 38282550
[TBL] [Abstract] [Full Text] [Related]
4. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
Wong RW; Cheung ANY
Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
[TBL] [Abstract] [Full Text] [Related]
5. Management of Bilateral Diffuse Uveal Melanocytic Proliferation (BDUMP)-A Case Report.
Drača N; Orešković EG; Lazić R; Vukojević M; Radolović Bertetić A; Vukojević N
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138261
[No Abstract] [Full Text] [Related]
6. [Risk factor analysis of lymph node metastasis in endometrial carcinoma combined with molecular types].
Li LL; Li H; Li J; Zhang XB; Wang ZQ; Shen DH; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):733-741. PubMed ID: 37849254
[No Abstract] [Full Text] [Related]
7. Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies.
Yang Y; Wu SF; Bao W
Int J Gynaecol Obstet; 2024 Feb; 164(2):436-459. PubMed ID: 37525501
[TBL] [Abstract] [Full Text] [Related]
8. [Uterine
Cao F; Zhong M; Liu CR
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):370-374. PubMed ID: 37042153
[TBL] [Abstract] [Full Text] [Related]
9. Cytopathological features associated with pole mutation in endometrial cancer.
Yanazume S; Iwakiri K; Kobayashi Y; Kitazono I; Akahane T; Mizuno M; Togami S; Tanimoto A; Kobayashi H
Cytopathology; 2023 May; 34(3):211-218. PubMed ID: 36727290
[TBL] [Abstract] [Full Text] [Related]
10. Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia.
Zhang X; Chen D; Zhao X; Wang C; He Y; Chen Y; Wang J; Shen D
Pathol Res Pract; 2023 Jan; 241():154278. PubMed ID: 36580798
[TBL] [Abstract] [Full Text] [Related]
11. ECPPF (E2F1, CCNA2, pole, PPP2R1A, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer.
Gonzalez-Bosquet J; Weroha SJ; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Yadav S; Couch FJ; Podratz KC
PLoS One; 2022; 17(12):e0278408. PubMed ID: 36454788
[TBL] [Abstract] [Full Text] [Related]
12. Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon?
Mueller JJ; Rios-Doria E; Park KJ; Broach VA; Alektiar KM; Jewell EL; Zivanovic O; Sonoda Y; Abu-Rustum NR; Leitao MM; Gardner GJ
Gynecol Oncol; 2023 Jan; 168():1-7. PubMed ID: 36334496
[TBL] [Abstract] [Full Text] [Related]
13. TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
Arciuolo D; Travaglino A; Raffone A; Raimondo D; Santoro A; Russo D; Varricchio S; Casadio P; Inzani F; Seracchioli R; Mollo A; Mascolo M; Zannoni GF
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232987
[TBL] [Abstract] [Full Text] [Related]
14. One-stop molecular classification of endometrial carcinoma using comprehensive next-generation sequencing.
Li Y; Chen R; Yuan M; Wang D; Fu C; Chen R; Lei C; Zhou Q
Int J Cancer; 2022 Dec; 151(11):1969-1977. PubMed ID: 36036365
[TBL] [Abstract] [Full Text] [Related]
15. Isolated splenic metastasis of endometrial cancer 12 years after treatment: A case report and literature review.
Teng X; Jiang M; Zhu X; Dou R; Yuan D; Huang J; Yu H
Medicine (Baltimore); 2022 Apr; 101(17):e29178. PubMed ID: 35512074
[TBL] [Abstract] [Full Text] [Related]
16. Clinicopathological and molecular characterization of high-grade endometrial carcinoma with pole mutation: a single center study.
Yu S; Sun Z; Zong L; Yan J; Yu M; Chen J; Lu Z
J Gynecol Oncol; 2022 May; 33(3):e38. PubMed ID: 35320887
[TBL] [Abstract] [Full Text] [Related]
17. Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers.
Farmanbar A; Firouzi S; Kneller R; Khiabanian H
J Transl Med; 2022 Feb; 20(1):65. PubMed ID: 35109853
[TBL] [Abstract] [Full Text] [Related]
18. Classification of high-grade endometrium carcinomas using molecular and immunohistochemical methods.
Bayramoglu D; Seçilmiş Kerimoğlu Ö; Bayramoğlu Z; Çintesun E; Şahin G; Karabağlı P; Çelik Ç
Ginekol Pol; 2023; 94(1):3-11. PubMed ID: 35072228
[TBL] [Abstract] [Full Text] [Related]
19. Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer.
Hwang GE; Lee JW; Jeon S; Cho IH; Kim HD
Doc Ophthalmol; 2022 Apr; 144(2):153-162. PubMed ID: 34997406
[TBL] [Abstract] [Full Text] [Related]
20. Strong expression of PD-L1 in invasive front of MELF pattern in endometrioid carcinoma.
Tahara S; Kohara M; Sato K; Morii E
Pathol Res Pract; 2022 Jan; 229():153699. PubMed ID: 34929601
[TBL] [Abstract] [Full Text] [Related]
[Next]
